SpringerLink
Log in

Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review

  • Systematic Review
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background

Tardive dyskinesia (TD) is a persisting, and potentially irreversible, movement disorder associated with treatment with dopamine receptor antagonists. Few data are available on the risk of TD in children and adolescents treated with antipsychotic medication.

Objective

To review the literature on incidence, risk factors, and treatment options for antipsychotic-associated TD in children and adolescents (aged < 18 years).

Methods

Relevant articles were identified through a systematic search of Embase and Medline performed in January 2024. Methodological quality was assessed using the Newcastle-Ottawa Scale and Joanna Briggs Institute Critical Appraisal tools.

Results

Thirteen studies were identified. The reported TD point prevalence was 5–20%, with higher rates in studies involving typical antipsychotics. Lower estimates (around 1%) emerged from analyses of clinical database data suggesting underdiagnosis in clinical practice. Risk factors included treatment with typical antipsychotics, higher doses, longer duration of exposure, older age, female gender, higher baseline Abnormal Involuntary Movements Scale (AIMS) scores, intellectual impairment, and perinatal complications.

Conclusion

Although relatively few cases have been reported in children and adolescents, TD remains a risk in this population. Individuals receiving antipsychotics should be monitored carefully for the emergence of abnormal movements. Other than dose reduction, discontinuation, or switch to a lower-risk antipsychotic, few interventions have demonstrated efficacy. The strongest evidence for pharmacological treatment is for VMAT-2 inhibitors (valbenazine and deutetrabenazine), but these drugs are not licensed for use in children. To reduce risk, antipsychotics should be prescribed only if necessary, at the minimum effective dose and for the minimum necessary duration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–47. https://doi.org/10.1007/s40263-018-0494-8.

    Article  CAS  PubMed  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  3. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486–7. https://doi.org/10.1001/archpsyc.1982.04290040080014.

    Article  CAS  PubMed  Google Scholar 

  4. Widschwendter CG, Hofer A. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. Curr Opin Psychiatry. 2019;32(3):179–84. https://doi.org/10.1097/yco.0000000000000491.

    Article  PubMed  Google Scholar 

  5. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.

    Article  PubMed  Google Scholar 

  6. Caroff SN, Ungvari GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018;389:4–9. https://doi.org/10.1016/j.jns.2018.02.015.

    Article  PubMed  Google Scholar 

  7. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. In: Weiner WJ, Tolosa E, editors. Handbook of clinical neurology. Elsevier; 2011. p. 601–16.

    Google Scholar 

  8. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;21(5):589–98. https://doi.org/10.1002/mds.20823.

    Article  PubMed  Google Scholar 

  9. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–8. https://doi.org/10.4088/jcp.v69n1008.

    Article  PubMed  Google Scholar 

  10. Chong S-A, Tay JAM, Subramaniam M, Pek E, Machin D. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009;29(1):5–8. https://doi.org/10.1097/JCP.0b013e3181929f94.

    Article  PubMed  Google Scholar 

  11. Chong S-A, Remington G, Mahendran R, Chua H-C. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol. 2001;21(2):235–7.

    Article  CAS  PubMed  Google Scholar 

  12. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76. https://doi.org/10.1007/s13311-013-0222-5.

    Article  CAS  PubMed  Google Scholar 

  13. Reich SG. Pearls: hyperkinetic movement disorders. Semin Neurol. 2010;30(1):15–22. https://doi.org/10.1055/s-0029-1245005.

    Article  PubMed  Google Scholar 

  14. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94(2):118–24. https://doi.org/10.1111/j.1600-0447.1996.tb09835.x.

    Article  CAS  PubMed  Google Scholar 

  15. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinetic Movements. 2014. https://doi.org/10.7916/D8MS3R8C.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–7. https://doi.org/10.1177/070674370505000907.

    Article  PubMed  Google Scholar 

  17. Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs. 2013;15(3):217–33. https://doi.org/10.1007/s40272-013-0024-6.

    Article  Google Scholar 

  18. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179–208. https://doi.org/10.2165/11585350-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  19. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651–68. https://doi.org/10.2165/11592020-000000000-00000.

    Article  PubMed  Google Scholar 

  20. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6. https://doi.org/10.1097/YCO.0b013e3282f53132.

    Article  PubMed  Google Scholar 

  21. Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647–56. https://doi.org/10.1089/cap.2006.0117.

    Article  PubMed  Google Scholar 

  22. Laboe C, Jain A, Cardiel SH. Masked tardive dyskinesia in the coronavirus disease 2019 era. Cureus. 2021;13(8): e16999. https://doi.org/10.7759/cureus.16999.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kakko K, Bjelogrlic-Laakso N, Pihlakoski L, Lehtimäki K, Järventausta K. Tardive dyskinesia should not be overlooked. J Child Adolesc Psychopharmacol. 2019;29(1):72–4. https://doi.org/10.1089/cap.2018.0084.

    Article  PubMed  Google Scholar 

  24. Kidd V. Risperidone-induced tardive dyskinesia in an autistic child. Prim Care Companion CNS Disord. 2018. https://doi.org/10.4088/PCC.18l02283.

    Article  PubMed  Google Scholar 

  25. Lamberti M, Di Rosa G, Cucinotta F, Pironti E, Galati C, Gagliano A. Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: a case report. Clin Psychopharmacol Neurosci. 2017;15(3):285–7. https://doi.org/10.9758/cpn.2017.15.3.285.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Pérez CA, Garcia SS, Yu RD. Extrapyramidal symptoms as a result of risperidone discontinuation during combination therapy with methylphenidate in a pediatric patient. J Child Adolesc Psychopharmacol. 2016;26(2):182. https://doi.org/10.1089/cap.2015.0225.

    Article  PubMed  Google Scholar 

  27. Tunc Z, Celik G, Avci A, Tahiroglu A, Gamli I. Supplementation of vitamin E and N-acetylcysteine with quetiapine in tardive dyskinesia: a case report. Klinik Psikofarmakoloji Bulteni. 2014;24:S350.

    Google Scholar 

  28. Aggarwal S, Burnett P. Tardive dyskinesia with atypical antipsychotics in youth. Australas Psychiatry. 2013;21(5):507–8. https://doi.org/10.1177/1039856213492864.

    Article  PubMed  Google Scholar 

  29. Tufan AE, Bilici R, Ugurlu GK, Yilmaz S, Erdogan A. Tardive dyskinesia due to olanzapine in an adolescent with psychosis and its treatment with clozapine. Arch Neuropsychiatry. 2013;50(2):183–6.

    Article  Google Scholar 

  30. Kwon H. Tardive dyskinesia in an autistic patient treated with risperidone. Am J Psychiatry. 2004;161(4):757–8. https://doi.org/10.1176/appi.ajp.161.4.757-a.

    Article  PubMed  Google Scholar 

  31. Borchardt CM, Jensen C, Dean CE, Tori J. Case study: childhood-onset tardive dyskinesia versus choreoacanthocytosis. J Am Acad Child Adolesc Psychiatry. 2000;39(8):1055–8. https://doi.org/10.1097/00004583-200008000-00022.

    Article  CAS  PubMed  Google Scholar 

  32. Kumar S, Malone DM. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J. 2000;76(895):316–7. https://doi.org/10.1136/pmj.76.895.316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone. J Clin Psychiatry. 1999;60(7):485–7. https://doi.org/10.4088/jcp.v60n0711b.

    Article  CAS  PubMed  Google Scholar 

  34. Feeney DJ, Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry. 1996;35(11):1421–2. https://doi.org/10.1097/00004583-199611000-00006.

    Article  CAS  PubMed  Google Scholar 

  35. MacEwan TH, Morton MJ. Use of clozapine in a child with treatment-resistant schizophrenia. Br J Psychiatry. 1996;168(3):376–8. https://doi.org/10.1192/bjp.168.3.376.

    Article  CAS  PubMed  Google Scholar 

  36. Levkovitch Y, Kronenberg J, Kayser N, Zvyagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Develop. 1995;17(3):213–5. https://doi.org/10.1016/0387-7604(95)00034-9.

    Article  CAS  Google Scholar 

  37. Towbin KE, Dykens EM, Pugliese RG. Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry. 1994;33(5):651–7. https://doi.org/10.1097/00004583-199406000-00005.

    Article  CAS  PubMed  Google Scholar 

  38. Lal S, AlAnsari E. Tourette-like syndrome following low dose short-term neuroleptic treatment. Can J Neurol Sci. 1986;13(2):125–8. https://doi.org/10.1017/S0317167100036052.

    Article  CAS  PubMed  Google Scholar 

  39. Monteiro LM. Tardive dyskinesia controlled by anticholinergic agents. Clin Neuropharmacol. 1985;8(4):372–6. https://doi.org/10.1097/00002826-198512000-00008.

    Article  CAS  PubMed  Google Scholar 

  40. Caine ED, Polinsky RJ. Tardive dyskinesia in persons with Gilles de la Tourette’s disease. Arch Neurol. 1981;38(7):471–2. https://doi.org/10.1001/archneur.1981.00510070105032.

    Article  CAS  PubMed  Google Scholar 

  41. Mizrahi EM, Holtzman D, Tharp B. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette’s disease. Arch Neurol. 1980;37(12):780. https://doi.org/10.1001/archneur.1980.00500610060010.

    Article  CAS  PubMed  Google Scholar 

  42. Petty LK, Spar CJ. Haloperidol-induced tardive dyskinesia in a 10-year-old girl. Am J Psychiatry. 1980;137(6):745–6. https://doi.org/10.1176/ajp.137.6.745.

    Article  CAS  PubMed  Google Scholar 

  43. George PP, DeCastro Molina JA, Heng BH. The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews. Indian J Ophthalmol. 2014;62(7):761–7. https://doi.org/10.4103/0301-4738.138615.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Wells G, Shea B, O'Connell D, Welch C, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 18 Jan 2024.

  45. Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin Pediatr. 1975;14(10):953–5. https://doi.org/10.1177/000992287501401013.

    Article  CAS  Google Scholar 

  46. Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry. 1991;148(10):1322–8. https://doi.org/10.1176/ajp.148.10.1322.

    Article  CAS  PubMed  Google Scholar 

  47. Dorevitch A, Meretyk I, Umansky Y, Galili-Weisstub E. Antipsychotic drugs and tardive dyskinesia: preliminary results in an adolescent psychiatric ward. J Clin Pharm Ther. 1995;20(2):63–5. https://doi.org/10.1111/j.1365-2710.1995.tb00630.x.

    Article  CAS  PubMed  Google Scholar 

  48. Gebhardt S, Härtling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. 2006;15(7):371–82. https://doi.org/10.1007/s00787-006-0544-5.

    Article  PubMed  Google Scholar 

  49. Gebhardt S, Härtling F, Hanke M, Theisen FM, von Georgi R, Grant P, et al. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. Eur Child Adolesc Psychiatry. 2008;17(1):44–53. https://doi.org/10.1007/s00787-007-0633-0.

    Article  PubMed  Google Scholar 

  50. Wonodi I, Reeves G, Carmichael D, Verovsky I, Avila MT, Elliott A, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007;22(12):1777–82. https://doi.org/10.1002/mds.21618.

    Article  PubMed  Google Scholar 

  51. Jerrell JM, Hwang T-L, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol. 2008;23(12):1392–9. https://doi.org/10.1177/0883073808319070.

    Article  PubMed  Google Scholar 

  52. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol Bull. 1995;31(2):363–9.

    CAS  PubMed  Google Scholar 

  53. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):835–43. https://doi.org/10.1097/00004583-199706000-00022.

    Article  CAS  PubMed  Google Scholar 

  54. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry. 2001;62(12):967–74. https://doi.org/10.4088/jcp.v62n1209.

    Article  CAS  PubMed  Google Scholar 

  55. Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, et al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol. 2015;35(6):686–93. https://doi.org/10.1097/jcp.0000000000000419.

    Article  CAS  PubMed  Google Scholar 

  56. Wei JY-J, Liu X, Rao N, Mcpherson M, Beth-Jones M, Bussing R, et al. Physical health outcomes in preschoolers with prior authorization for antipsychotics. Pharmacoepidemiol Drug Saf. 2017;26:272–3. https://doi.org/10.1002/pds.4275.

    Article  Google Scholar 

  57. North CS, McDonald K, Hunter J, Burruss J. Prevalence of tardive dyskinesia in an electronic medical record study at a large community mental health treatment center. Prim Care Companion CNS Disord. 2022. https://doi.org/10.4088/PCC.21m03069.

    Article  PubMed  Google Scholar 

  58. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am J Psychiatry. 1988;145(5):621–4. https://doi.org/10.1176/ajp.145.5.621.

    Article  CAS  PubMed  Google Scholar 

  59. McDermid SA, Hood J, Bockus S, D’Alessandro E. Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia? Can J Psychiat. 1998;43(6):629–31. https://doi.org/10.1177/070674379804300613.

    Article  CAS  Google Scholar 

  60. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54(4):133–9.

    CAS  PubMed  Google Scholar 

  61. Magulac M, Landsverk J, Golshan S, Jeste D. Abnormal involuntary movements in neuroleptic-naive children and adolescents. Can J Psychiat. 1999;44(4):368–73.

    Article  CAS  Google Scholar 

  62. Puri BK, Barnes TR, Chapman MJ, Hutton SB, Joyce EM. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry. 1999;66(1):76–8. https://doi.org/10.1136/jnnp.66.1.76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):264–78.

    Article  Google Scholar 

  64. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–40. https://doi.org/10.1002/wps.20579.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–7. https://doi.org/10.1016/j.jns.2018.02.012.

    Article  PubMed  Google Scholar 

  66. Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr. 2019;42(2):56–61. https://doi.org/10.18773/austprescr.2019.014.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Friedman JH. Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Parkinsonism Relat Disord. 2020;79:60–4. https://doi.org/10.1016/j.parkreldis.2020.08.031.

    Article  PubMed  Google Scholar 

  68. Frei K. Tardive dyskinesia: Who gets it and why. Parkinsonism Relat Disord. 2019;59:151–4. https://doi.org/10.1016/j.parkreldis.2018.11.017.

    Article  PubMed  Google Scholar 

  69. Tsermpini EE, Redenšek S, Dolžan V. Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2021.834129.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Zai CC, Maes MS, Tiwari AK, Zai GC, Remington G, Kennedy JL. Genetics of tardive dyskinesia: promising leads and ways forward. J Neurol Sci. 2018;389:28–34. https://doi.org/10.1016/j.jns.2018.02.011.

    Article  CAS  PubMed  Google Scholar 

  71. Etminan M, Procyshyn RM, Samii A, Carleton BC. Risk of extrapyramidal adverse events with aripiprazole. J Clin Psychopharmacol. 2016;36(5):472–4. https://doi.org/10.1097/JCP.0000000000000543.

    Article  CAS  PubMed  Google Scholar 

  72. Lanning RK, Zai CC, Müller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics. 2016;17(12):1339–51. https://doi.org/10.2217/pgs.16.26.

    Article  CAS  PubMed  Google Scholar 

  73. Mackenzie B, Souza RP, Likhodi O, Tiwari AK, Zai CC, Sturgess J, et al. Pharmacogenetics of antipsychotic treatment response and side effects. Therapy. 2010;7(2):191–8. https://doi.org/10.2217/thy.10.3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25. https://doi.org/10.1176/appi.ajp.161.3.414.

    Article  PubMed  Google Scholar 

  75. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: review and update. Am J Psychiatry. 1980;137(8):900–8. https://doi.org/10.1176/ajp.137.8.900.

    Article  CAS  PubMed  Google Scholar 

  76. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372–94. https://doi.org/10.1089/cap.2004.14.372.

    Article  PubMed  Google Scholar 

  77. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009;19(6):611–21. https://doi.org/10.1089/cap.2008.0144.

    Article  PubMed  Google Scholar 

  78. Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs. 2016;30(9):807–18. https://doi.org/10.1007/s40263-016-0367-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Stämpfli D, Weiler S, Burden AM. Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. Eur Child Adolesc Psychiatry. 2021;30(7):1047–58. https://doi.org/10.1007/s00787-020-01589-2.

    Article  PubMed  Google Scholar 

  80. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379–85.

    Article  CAS  PubMed  Google Scholar 

  81. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23–45. https://doi.org/10.2165/00023210-200216010-00003.

    Article  CAS  PubMed  Google Scholar 

  82. Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. J Psychopharmacol. 2019;33(10):1187–98. https://doi.org/10.1177/0269881119862535.

    Article  CAS  PubMed  Google Scholar 

  83. Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785–94. https://doi.org/10.2147/NDT.S196541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders: compendium. American Psychiatric Publishing; 2000.

    Google Scholar 

  85. Tenback D, van Harten P, Slooff C, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010;24(7):1031–5. https://doi.org/10.1177/0269881109106306.

    Article  CAS  PubMed  Google Scholar 

  86. Pringsheim T, Doja A, Belanger S, Patten S. The Canadian Alliance for Monitoring Effectiveness, Safety of Antipsychotics in Children guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics Child Health. 2011;16(9):590–8. https://doi.org/10.1093/pch/16.9.590.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD000205.pub2.

    Article  PubMed  PubMed Central  Google Scholar 

  88. **ang H, Zhen C. Clonazepam therapy of tardive dyskinesia: a double-blind trial. West China Med J. 1997;12(1):17–8.

    Google Scholar 

  89. British National Formulary (BNF). Treatment summary: hypnotics and anxiolytics. https://bnf.nice.org.uk/treatment-summaries/hypnotics-and-anxiolytics/. Accessed 26/12/2022 2022.

  90. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54. https://doi.org/10.4088/jcp.v69n0405.

    Article  CAS  PubMed  Google Scholar 

  91. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21(8):1219–21. https://doi.org/10.1002/mds.20835.

    Article  PubMed  Google Scholar 

  92. Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. 2006;29(5):265–8. https://doi.org/10.1097/01.Wnf.0000228807.49044.7d.

    Article  CAS  PubMed  Google Scholar 

  93. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65(1):92–6. https://doi.org/10.4088/jcp.v65n0116.

    Article  CAS  PubMed  Google Scholar 

  94. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry. 2014;48(12):1096–114. https://doi.org/10.1177/0004867414548902.

    Article  PubMed  Google Scholar 

  95. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016;68(3):563–602. https://doi.org/10.1124/pr.115.012021.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Lyseng-Williamson KA. Levetiracetam. Drugs. 2011;71(4):489–514. https://doi.org/10.2165/11204490-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  97. Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD000459.pub3.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Glazer WM, Moore DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia: a discontinuation study. Arch Gen Psychiatry. 1984;41(6):623–7. https://doi.org/10.1001/archpsyc.1984.01790170097011.

    Article  CAS  PubMed  Google Scholar 

  99. Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–92. https://doi.org/10.1192/bjp.157.4.585.

    Article  CAS  PubMed  Google Scholar 

  100. Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatric Clinics. 2016;39(3):391–411. https://doi.org/10.1016/j.psc.2016.04.003.

    Article  PubMed  Google Scholar 

  101. Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388–99. https://doi.org/10.1177/0706743719828968.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306. https://doi.org/10.1186/s12888-018-1889-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.

    PubMed  PubMed Central  Google Scholar 

  104. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76(7):779–87. https://doi.org/10.1007/s40265-016-0568-1.

    Article  CAS  PubMed  Google Scholar 

  105. Mentzel TQ, van der Snoek R, Lieverse R, Oorschot M, Viechtbauer W, Bloemen O, et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry. 2018. https://doi.org/10.4088/JCP.17r11852.

    Article  PubMed  Google Scholar 

  106. O’Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7. https://doi.org/10.1002/mds.26330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84. https://doi.org/10.1176/appi.ajp.2017.16091037.

    Article  PubMed  Google Scholar 

  108. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. The ARM-TD study. Neurology. 2017;88(21):2003–10. https://doi.org/10.1212/wnl.0000000000003960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. https://doi.org/10.1016/S2215-0366(17)30236-5.

    Article  PubMed  Google Scholar 

  110. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–38. https://doi.org/10.2147/dddt.S133205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD000209.pub3.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Adelufosi AO, Abayomi O, Ojo TMF. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015. https://doi.org/10.1002/14651858.CD010501.pub2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. East London NHS Foundation Trust, 9 Rush Court, Bedford, MK40 3JT, UK

    Frank M. C. Besag & Michael J. Vasey

  2. University College London, London, UK

    Frank M. C. Besag

  3. King’s College London, London, UK

    Frank M. C. Besag

  4. East London NHS Foundation Trust, Newham, London, UK

    Iffah Salim

  5. Institute of Mental Health, School of Medicine, NIHR MindTech HealthTech Research Centre, University of Nottingham, Innovation Park, Triumph Road, Nottingham, UK

    Chris Hollis

  6. Institute of Mental Health, NIHR Nottingham Biomedical Research Centre, University of Nottingham, Innovation Park, Triumph Road, Nottingham, UK

    Chris Hollis

  7. Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK

    Chris Hollis

Authors
  1. Frank M. C. Besag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Vasey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iffah Salim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chris Hollis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank M. C. Besag.

Ethics declarations

Funding

No funding was received in relation to the preparation of this manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Ethics Approval

Ethics approval for publication of the case report was obtained from the East London NHS Foundation Trust Governance and Ethics Committee for Studies and Evaluations (GECSE), reference G2402c.

Consent to Participate

Written consent was granted by the adults with parental responsibility for the child in the case report. The child had intellectual disability and did not have the mental capacity to provide consent himself.

Consent for Publication

Written informed consent to publish details of the case report described in this article was obtained from the adults with parental responsibility for the child.

Availability of Data and Material

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Code Availability

Not applicable.

Authors Contribution

All authors participated in the drafting and editing of the manuscript and approved the final version for submission. The literature search and screening of articles was performed by FB and MV. Quality assessment was performed by MV and IS. All authors read and approved the final version of the manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Besag, F.M.C., Vasey, M.J., Salim, I. et al. Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review. Drug Saf (2024). https://doi.org/10.1007/s40264-024-01446-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40264-024-01446-0

Search

Navigation